Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Dense Epirubicin and Paclitaxel vs Standard EC-Paclitaxel in Adjuvant Breast Cancer
NCT00668616Phase 3Completed
- Sponsor
- NOGGO
- Start
- Mar 2000
- Primary completion
- Jul 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epirubicin and paclitaxel in breast cancer (2 arms), sponsored by NOGGO. Primary endpoint: Progression-Free Time. Started Mar 2000; status: completed.
02
Drugs
epirubicinpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00668616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00668616.